Abstract 865P
Background
The prognosis of early OSCC is strongly correlated with local disease control. However, patients with T1-T2 OSCC and clear margins have a 5-year local relapse rate of around 15%. The evaluation of the quality of surgical resection is therefore essential.
Methods
A prospective multicenter trial based on patients with T1-T2 OSCC treated surgically with clear margins, showed the interest of a molecular analysis (microsatellite instability (MSI)) of surgical margins to evaluate the minimal residual disease (MRD) while adapting the postoperative strategy (NCT00232960). Recently, innovative techniques for detecting circulating tumor DNA have been developed. Our main objective was, then, to evaluate the feasibility of detecting MRD by identifying specific molecular abnormalities with Whole Exom Sequencing (WES) and Shallow Whole Genome Sequencing (ShWGS) in the primary tumor and looking for it on the margins.
Results
310 patients were included initially with 216 tumor/margins samples available for molecular analysis. Tumor was informative for MSI analysis in 63% of cases (n=133). Positive molecular margins were observed in 23 cases, leading to a postoperative treatment. Median follow-up was 58 months [30;83]. In informative tumor, molecularly driven treatment seemed to lower the 5-year local recurrence rate from 14.1% to 6.4% (p=0.15). Among the initial cohort, 108 primary tumors were secondary screened by WES with an informative rate of 78.6%. With a 10X depth for molecular analysis, we observed 13 patients with at least one positive margin. Then, analyzing retrospectively the oncologic outcomes, we observed a significant benefit for local control at 5 years for patients with WES negative margins (91.7% versus 64.1%, p=0.02). We, then, performed a ShWGS analysis on a sub-group of 39 patients. Patients with positive margins both in WES and ShWGS had a higher risk of local relapse at 5 years (p<10-3).
Conclusions
Molecular analysis of surgical margins for early OSCC lead to a better assessment of microscopic residual disease while postoperative decision making according to WES and ShWGS could improve local control.
Clinical trial identification
NCT00232960.
Editorial acknowledgement
Legal entity responsible for the study
GETTEC group (French Group for Study of Head and Neck Tumors).
Funding
PHRC program from INCA (French National Cancer Institute) PRISM program from Gustave Roussy Cancer Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12